Key highlights
- Consortium (Willemen, Cordeel, Imtech, SPIE) selected to build the PanTera facility producing actinium-225 for targeted cancer therapies.
- PanTera is a spin-off of IBA and SCK CEN aiming to scale actinium-225 production to meet growing clinical demand.
- Construction in Mol is underway (basement stage); SPIE will integrate HVAC, sanitation and technical gas systems, with equipment integration scheduled by end-2026 using prefabrication.
- Design by Modulo with Tractebel as engineering consultant; site energy will use heat pumps and air handling units.
Project overview
PanTera, a spin-off of IBA and SCK CEN, will build a facility in Mol to produce actinium-225 for targeted cancer therapies and scale production to meet growing clinical demand.
Consortium and roles
The construction consortium comprises Willemen, Cordeel, Imtech and SPIE; SPIE is tasked with heating, cooling, ventilation, sanitation and technical gas installations for the facility.
Design and engineering
Modulo is the architect and Tractebel the engineering consultant; the site’s energy concept includes heat pumps and air handling units to support efficient operation.
Schedule and execution
Basement construction is underway and SPIE plans to start equipment integration by the end of 2026, using prefabrication to enhance operational efficiency and quality control.
